566 related articles for article (PubMed ID: 26469277)
1. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):127-34. PubMed ID: 26174631
[TBL] [Abstract][Full Text] [Related]
3. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
4. Patent life of antiretroviral drugs approved in the US from 1987 to 2007.
Rodriguez-Monguio R; Seoane-Vazquez E
AIDS Care; 2009 Jun; 21(6):760-8. PubMed ID: 19499381
[TBL] [Abstract][Full Text] [Related]
5. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
6. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
7. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
8. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
9. Recent trends in brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R
J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
[TBL] [Abstract][Full Text] [Related]
10. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
Olsen A; Beall RF; Knox RP; Tu SS; Kesselheim AS; Feldman WB
PLoS Med; 2023 Nov; 20(11):e1004309. PubMed ID: 37971985
[TBL] [Abstract][Full Text] [Related]
11. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
[TBL] [Abstract][Full Text] [Related]
12. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
13. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
Yamanaka T; Kano S
Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
[TBL] [Abstract][Full Text] [Related]
14. Examination of risk evaluation and mitigation strategies and drug safety in the US.
Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
16. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
17. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
Wolff ME
J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
20. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
